One-year data from a large real-world dataset provide reassurance that clinical outcomes with the new-generation LAA occlusion device for stroke prevention compare well with those from pivotal trials.
Interim data from a large real-world dataset provide reassurance about acute and subacute procedural outcomes with the new-generation LAA occlusion device for stroke prevention.
Our world-leading experience in this procedure confirms that it reduces stroke risk in high-risk patients and can be safely combined with TAVR as well as atrial fibrillation ablation.
Patients with a history of intracranial hemorrhage have had few safe treatment options for nonvalvular atrial fibrillation. A new study of the Watchman device suggests that may be changing.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Findings from three Cleveland Clinic real-world studies suggest a wider range of patients stand to benefit from the left atrial appendage closure device.
The newly approved WATCHMAN™ device can prevent stroke in high-risk patients with nonvalvular atrial fibrillation. But when exactly is left atrial appendage closure preferable to warfarin therapy?